2409099-32-5

Semzuvolimab is a human IgG1κ antibody, targeting to p55, T cell surface antigen T4/Leu-3 (CD4). Human CD4 antibodies can neutralize HIV infection and have the potential to inhibit HAART stable HIV infection[1][2].

[1] Wang Changyi, et al. Treatment and sustained virologic remission of HIV infection by antibodies to CD4 in HAART stabilized patients. World Intellectual Property Organization, WO2018035001 A1. 2018-02-22.
[2] Semzuvolimab. IMGT/mAb-DB.